The drug from coronavirus infection "Favipiravir" may appear on the market earlier than expected. RIA "news" in a press-service of the Ministry of health of the country.
Currently, the drug is not registered and is undergoing clinical trials. The expected total duration of studies is six months or a year. However, it already get infected with coronavirus people who are involved in the research.
As explained in Department, the study drug may continue after its registration. Positive results of researches will allow to initiate the procedure of state registration with the establishment of post-marketing measures.
"This will significantly reduce the time to market of a medicinal product", – concluded the Ministry.
The Chinese authorities announced the outbreak of pneumonia in Wuhan on 31 December 2019. The causative agent is a new type of coronavirus SARS-CoV-2, which causes the disease COVID-19. Subsequently, on 11 March, the who announced the outbreak of a new coronavirus pandemic. All in the world found more than 5.2 million cases of infection, and in Russia — more than 326 thousand cases.